AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M

ANGIODYNAMICS INC

2024-FY EPS reported -$4.59 revenue$303,914,000

Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.
FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.
Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.
Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.